Roberta Joppi
Mario Negri Institute for Pharmacological Research
Publications 35
#1William H. ShrankH-Index: 53
#2Brian GodmanH-Index: 39
Last.Marija KalabaH-Index: 14
view all 23 authors...
AimThe aim of this article was to evaluate the influence of different demand-side measures to enhance the prescribing of generics in ambulatory care based on cross-national comparisons. Methods An observational retrospective study was conducted using administrative databases from across Europe, documenting changes in reimbursed utilization and expenditure of different proton pump inhibitors (PPIs) and statins between 2001 and 2007, alongside different reforms to enhance prescribing efficiency. U...
#1Brian Godman (Strathclyde Institute of Pharmacy and Biomedical Sciences)H-Index: 39
#2Andrew F. HillH-Index: 67
Last.Alan Haycox (University of Strathclyde)
view all 48 authors...
Introduction: There are appreciable concerns among European health authorities with growing expenditure on cancer medicines and issues of sustainability. The enhanced use of low cost generics could help. Aims: Consequently, there is a need to comprehensively document current and future arrangements regarding the pricing of generic cancer medicines across Europe, and whether these are indication specific, as well as how this translates into actual prices to provide future direction. Methodology: ...
#1Patricia Vella Bonanno (Strathclyde Institute of Pharmacy and Biomedical Sciences)H-Index: 6
#2Anna BucsicsH-Index: 15
Last.Brian GodmanH-Index: 39
view all 36 authors...
ABSTRACTIntroduction: In January 2018 the European Commission published a Proposal for a Regulation on Health Technology Assessment (HTA): ‘Proposal for a Regulation on health technology assessment...
2 CitationsSource
Objectives As healthcare decision makers continue to face challenges in health services delivery to their patients, disinvestment programs are being established for a sustainable healthcare system. This study aimed to collect data and information by means of a survey of disinvestment candidates and ongoing disinvestment projects in the health technology assessment (HTA) community. Methods An online survey was conducted to collect information on disinvestment candidates and activities from member...
#1Brian Godman (Strathclyde Institute of Pharmacy and Biomedical Sciences)H-Index: 39
#2Anna BucsicsH-Index: 15
Last.Alan Haycox (University of Liverpool)H-Index: 36
view all 50 authors...
Introduction: There is continued unmet medical need for new medicines across countries especially for cancer, immunological diseases and orphan diseases. However, there are growing challenges with funding new medicines at ever increasing prices along with funding increased medicine volumes with the growing prevalence of both infectious diseases and non-communicable diseases across countries. This has resulted in the development of new models to better manage the entry of new medicines, new finan...
11 CitationsSource
Abstract Background Pulmonary arterial hypertension (PAH) is a life-threatening rare disease. Between 2001 and 2016 the European Medicines Agency (EMA) approved nine drugs to treat PAH. Considering the poor prognosis of patients with PAH it would be useful to understand whether the approved therapies can change the natural history of the disease. We assessed the therapeutic value and the quality of the evidence on medicines that have been authorized by the EMA in the 2000s. Methods Information a...
1 CitationsSource
#1Tomasz Bochenek (Jagiellonian University Medical College)H-Index: 10
#2Vafa AbilovaH-Index: 3
Last.Brian Godman (Strathclyde Institute of Pharmacy and Biomedical Sciences)H-Index: 39
view all 44 authors...
Drug shortages have been identified as a public health problem in an increasing number of countries. This can negatively impact on the quality and efficiency of patient care, as well as contribute to increases in the cost of treatment and the workload of health care providers. Shortages also raise ethical and political issues. The scientific evidence on drug shortages is still scarce, but many lessons can be drawn from cross-country analyses. The objective of this study was to characterize, comp...
6 CitationsSource
#1P. Vella Bonnano (Strathclyde Institute of Pharmacy and Biomedical Sciences)H-Index: 1
#2Michael ErmischH-Index: 2
Last.Alan Haycox (University of Liverpool)H-Index: 36
view all 38 authors...
Medicines receiving a conditional marketing authorisation through Medicines Adaptive Pathways to Patients (MAPPs) will be a challenge for payers. The ‘introduction’ of MAPPs is already seen by the European Medicines Agency (EMA) as a fait accompli, with payers not consulted or involved. However, once medicines are approved through MAPPs, they will be evaluated for funding by payers through different activities. These include Health Technology Assessment (HTA) with often immature clinical data an...
12 CitationsSource
#1Roberta JoppiH-Index: 16
#2Vittorio BerteleH-Index: 19
Last.Silvio GarattiniH-Index: 2
view all 3 authors...